A Secondary Checkpoint Refines CRISPR Precision
CMN Briefs
Apr. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CRISP-HR Therapeutics
Main focus: Next-generation gene editing
Company stage: Pre-clinical
Diseases (gene editing): Rare diseases and metabolic indications, specifically liver and pancreatic disorders
Genome editing tool: CRISPR-Cas9-HR
Funding stage: Private
Location: San Carlos, CA, USA
Website: https://www.crisp-hr.com/
CRISP-HR Therapeutics has developed a novel CRISPR-Cas9 system that favours the cellular repair mechanism called homologous recombination (HR) over another mechanism called non-homologous end joining (NHEJ), enabling higher rates of transgene insertions. While the company yet has to disclose its lead programmes, it has revealed that it will initially focus on rare disease and metabolic conditions.
